Pharmaceuticals Company Announces Shareholder Approval of Oncology Merger

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company"), a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, has recently announced that shareholders of TenX Keane Acquisition ("TenX"), a publicly traded special purpose acquisition company (SPAC), have voted to approve the previously disclosed business combination with Citius Pharma's oncology subsidiary. This merger will result in the formation of a new public entity, Citius Oncology, Inc. ("Citius Oncology"), which will continue to trade on the Nasdaq stock exchange under the symbol CTXR. $TENK.US$